Strategies for Treating Head & Neck Adenoid Cystic Carcinoma

ReachMD Healthcare Image


"Proton therapy [...] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] [...]"

BUFFALO, NY- August 4, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 28, 2023, entitled, "Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with variable localizations."

In this new editorial, researchers Florian Dudde, Kai-Olaf Henkel and Filip Barbarewicz from the Army Hospital Hamburg discuss head and neck tumors, which are among the most common malignancies. In this anatomical region, squamous cell carcinoma (SCC) is the most common malignant entity. However, there are also other malignant tumors that, unlike SCC, originate in the salivary glands of the head and neck region, such as mucoepidermoid carcinoma or adenoid cystic carcinoma (ACC).

In general, tumors originating from the minor salivary glands often show a higher degree of malignancy than tumors of the major salivary glands (parotid gland, submandibular gland, sublingual gland). Consequently, the ACC in particular is often localized in the area of the hard palate (small salivary glands). In rare cases, ACC has also been described in other regions of the head and neck region, such as the paranasal sinuses or the tongue.

"In principle, ACC grow slowly and consequently often cause a lack of clinical symptoms."

Their perivascular and perineural growth pattern can present therapeutic challenges, particularly in the head and neck region. The treatment of ACC in the head and neck region consists of surgical tumor resection with subsequent neck dissection and one- or two-stage plastic defect reconstruction. Severe ACC often require adjuvant radiotherapy.

"Proton therapy, as a special form of radiotherapy, seems to have decisive advantages with regard to the long-term survival of this highly malignant tumor originating from the small salivary glands."

Continue reading: DOI:

Correspondence to: Florian Dudde

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full



Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free